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Abstract 
 
This manuscript describes the synthesis, 3D-derived QSAR, antiproliferative activity 
and DNA binding properties of 2-amino, 5-amino and 2,5-diaminosubstituted 
benzimidazo[1,2-a]quinolines prepared by microwave assisted amination. Their 
antiproliferative effect was assessed on three tumor cell lines against colon, lung and breast 
carcinoma cell lines in vitro. The activities tested ranged from moderate to very strong. 2-
amino-subsituted analogues demonstrated stronger antiproliferative activity compared to 5-
amino, or 2,5-diamino substituted derivatives, while N-methyl or 3,5-dimethylpiperazinyl 
substituted analogues were the most active ones. Their DNA binding abilities and mode of 
interaction were evaluated using spectroscopic (melting temperature studies, UV/Visible and 
fluorescence spectra analyses, circular dichroism) and biochemical experiments 
(topoisomerase I-mediated DNA relaxation and DNase I footprinting experiments). From this 
series, only two compounds (36 and 37) evidenced strong DNA binding properties. Both 36 
and its iodide salt 37 intercalate between adjacent base pairs of the DNA helix but the 37 did 
not show any effect on tumor cells. Only compound 33 presented a very weak topoisomerase 
I poisoning activity. 3D-QSAR analysis identified hydrogen bonding properties, 
hydrophobicity, molecular flexibility, and distribution of hydrophobic regions as the 
molecular properties with the highest influence on the antiproliferative activity against all 
three studied cell lines. 
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1. Introduction 
Benzimidazole scaffold represents one of the most important structural motifs widely 
existing in a variety of bioactive natural products and numerous of synthetic medical and 
biochemical agents possessing different chemical and pharmacological features [1–5]. 
Importantly, due to the fact that benzimidazoles are structural isosters with naturally occurring 
nucleotides, their derivatives play a crucial role in the function of many biologically important 
molecules and can easily interact with biomolecules like DNA, RNA or different proteins of 
the living systems. DNA molecule, which plays a central role in life processes, is still one of 
the principal targets in anticancer drug development strategies [6]. Thus, the understanding of 
the molecular basis for cytotoxicity by anticancer agents is very important for the rational 
development of novel, more selective and efficient agents with greater specificity of action 
[7]. The most used classes of chemotherapeutic agents comprise molecules that interact with 
DNA like intercalators, alkylating agents or groove binders [8]. Organic intercalators are a 
class of polyaromatic compounds which usually consist of planar and fused aromatic or 
heteroaromatic rings that can insert or intercalate between two adjacent base pairs of duplex 
DNA and inhibit nucleic acid synthesis [9]. The incorporation of the benzimidazole nuclei 
with another heteroaromatic skeleton is an important synthetic strategy in drug discovery and 
can lead to highly conjugated, planar benzannulated benzimidazoles, which have the ability to 
intercalate between adjacent DNA base pairs. High fluorescence intensity and possibility of 
interaction with important biomacromolecules of the living systems offer also their potential 
use as a fluorescent probes for detection of biological important molecules as DNA or 
different proteins in biomedicinal diagnostics [10, 11]. Moreover, quinolines as a one of the 
most important groups of nitrogen heterocycles, are important structural units widely existing 
in natural alkaloids, therapeutics and synthetic analogues with wide range of biological 
activities and have a great importance in the natural, medicinal and environmental sciences.  
Quinoline-fused benzimidazoles, recently prepared and published in our research 
group, showed to be a very promising class of tetracyclic intercalators while biological 
activity studies comprising cytostatic evaluation, DNA/RNA interaction study, inhibition of 
topoisomerase I and II and proteomic profiling confirmed the anticancer potential of this class 
of compounds. Positively charged amidino substituted benzimidazo[1,2-a]quinolines 
intercalate into double-stranded DNA or RNA with the pronounced selectivity towards colon 
carcinoma cells, inhibited topoisomerase II and induced strong G2/M cell cycle arrest [12]. 
Very recently we have reported on the biological activity of 2-aminobenzimidazo[1,2-
a]quinoline-6-carbonitriles with different lengths of the secondary or tertiary amino chains 
linked to the tetracyclic skeleton which significantly influenced the antiproliferative activity 
in submicromolar range of concentrations [13]. To study the influence of position change of 
amino substituents on the tetracyclic skeleton, we have also published the synthesis, 
antiproliferative activity and DNA binding properties of 5-aminobenzimidazo[1,2-
a]quinoline-6-carbonitriles which showed moderate antiproliferative effect toward human 
cancer cell lines [14]. 
As a continuation of further development of these type of compounds and 
consideration of anticancer potential of benzimidazo[1,2-a]quinoline skeleton as a promising 
lead structure in the search for more selective and efficient chemotherapeutics, within this 
manuscript we have described the synthesis, antiproliferative effect and DNA binding 
properties of 2-amino, 5-amino and mostly 2,5-diamino substituted benzimidazo[1,2-
a]quinolines. All newly synthesized compounds were tested for their antiproliferative activity 
on the panel of three human tumour cell lines and for each cell line 3D-QSAR models were 
obtained.  
 
2. Results and discussion 
2.1. Chemistry 
 
All newly prepared compounds were synthesized according to the two main 
procedures shown in Scheme 1 and Scheme 2, by the conventional methods of organic 
synthesis for the preparation of similar benzimidazole derivatives, starting from 4-
fluorobenzaldehyde 1 or benzoylchlorides 10–11 and 2-cyanomethylbenzimidazole 2 which 
gave in the aldol reaction, in absolute ethanol using piperidine as a base, acyclic 
benzimidazole derivatives 3 and 12–13 in good yields (75%, 44%, 49%). 2-
Fluorobenzimidazo[1,2-a]quinoline 4 (72%) as a main precursor for the synthesis of 2-
aminobenzimidazo[1,2-a]quinolines was prepared by thermic cyclization in sulfolane from 
acyclic precursor 3. Fused keto substituted benzimidazo[1,2-a]quinolines 14 and 15 were 
prepared by thermic cyclization in DMF using t-KOBu as a base from acyclic precursors 12 
and 13 in good yields (57% and 96%). The main precursors for the synthesis of 5-amino and 
2,5-diaminobenzimidazo[1,2-a]quinolines, chloro substituted benzimidazo[1,2-a]quinolines 
16 (70%) and 17 (96%), were prepared in the reaction of compounds 14 and 15 with the 
POCl3 and PCl5. 
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Scheme 1. 
 
Based on the series of experiments which were undertaken in order to optimize the reaction 
times and yields and the fact that microwave synthesis provided shorter reaction time, highly 
increased yield as well as simple product isolation procedure, targeted amino and diamino 
substituted benzimidazo[1,2-a]quinolines 5–9 and 18–39 were finally prepared by using 
uncatalyzed microwave assisted amination in low to moderate yields (15% to 74%). This 
reaction was performed in acetonitrile with five to sevenfold excess of the corresponding 
amine by using 800 W power, 170 °C and 40 bar. N,N-dimethylated piperazinyl substituted 
compound 37 as a iodide salt was prepared from derivative 36 with an excess of methyl-
iodide in 47% yield.  
The structures of all prepared compounds were determined by the NMR analysis based on the 
analysis of H-H coupling constants as well as chemical shifts and by mass spectroscopy.
 
The 
reaction of cyclization of acyclic precursors provides a downfield shift of the aromatic protons 
and disappearance of one proton of the NH group on the benzimidazole nuclei which 
confirmed the formation of the benzimidazo[1,2-a]quinoline skeleton. Generally, 
1
H NMR 
spectra of all amino substituted benzimidazo[1,2-a]quinolines 5–9 and 18–39 showed a 
downfield shift of the aromatic protons in comparison to halogeno substituted precursor 4 and 
16 and 17. Also, it can be observed the appearance of protons related to amino substituents in 
the aliphatic part both in 
1
H and 
13
C NMR.  
1
H NMR spectra of  tertiary amino substituted derivatives 21–22 and 33–39 showed a 
downfield shift of the H-1, H-3, H-4 and H-5 protons of quinoline part of molecule.  
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Scheme 2. 
 
2.2. 3D-QSAR analysis 
In order to explore physical and chemical properties with the highest influence on 
antiproliferative activities of investigated benzimidazo[1,2-a]quinolines, 3D-QSAR analysis 
was performed. Using antiproliferative activities of the compounds presented in this paper and 
similar compounds whose antiproliferative activities were previously measured in the same 
laboratory [13, 14], 3D-QSAR models were derived (Table 1, Figure 1).  3D-QSAR models 1, 
2, and 3 were derived using antiproliferative activity data against H460, HCT 116 and MCF-7 
cell lines, respectively. 
Table 1. Statistical properties of 3D-QSAR models. 
Cell line Model nO 
a 
LV 
b 
R 
2   
Q 
2 c
 SDEC
d 
SDEP
e 
H460 1 49 5 0.817 0.489 0.345 0.577 
HCT 116 2 50 5 0.790 0.427 0.370 0.611 
MCF-7 3 50 5 0,857 0.614 0.266 0.437 
a 
Number of objects used to build the model. 
b 
Number of latent variables. 
c 
Q
2
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Figure 1. Predicted vs experimental antiproliferative activity (expressed as pIC50 – negative 
logarithmic value of concentration that causes 50% growth inhibition of the tumor cell lines 
of: A) model 1 (H460), B) model 2 (HCT 116), and C) model 3 (MCF-7).   
QSAR analysis of the obtained models identified the molecular properties with the highest 
influence on antiproliferative activities against studied cell lines (Figure 2A). In case of model 
1 (H460 cell line), the descriptors with the highest positive influence on antiproliferative 
activity are: molecular flexibility (FLEX_RB), descriptors related to H-bond properties 
(WN5, WN6, WO1-4, DRDRDO, DRACAC, DRACDO, ACACDO, ACACAC), protein 
binding (PB) and hydrophobicity (D3-7, ID2-4, CD3-6). The descriptors with the highest 
negative influence on antiproliferative activity against H460 cell line are: percentage of 
unionized species at different pH values (%FU4, %FU5), amphiphilic moment (A- vector that 
connects the center of hydrophobic and center of hydrophilic regions), and ratio of molecular 
volume and molecular surface (R). Similar descriptors are found as important for the activity 
against cell line HCT 116 cell line (Figure 2B). The highest positive influence have the 
descriptors related to H-bonding properties (WN6, WO1-WO5, DRDRDO, DRACAC, 
DRACDO, ACACDO, ACACAC), molecular flexibility (FLEX_RB), hydrophobic regions 
(D3-D8, ID3, ID4, CD3, CD4, DD1-DD4), and protein binding (PB), while the highest 
negative influence have the percentage of unionized species at different pH values (%FU4, 
%FU5), amphiphilic moment (A), and integy moment (ID1 - vector that connects the center 
of a molecule and the center of hydrophobic regions). In the case of the MCF-7 cell line 
(Figure 2C), again the descriptors related to H-bonds properties (WN6, WO1-WO5, 
DRDRDO, DRACAC, DRACDO, ACACDO, ACACAC), molecular flexibility (FLEX_RB), 
hydrophobicity (D3-D8, ID3, ID4, CD3, CD4, DD1-DD4), and protein binding (PB) have the 
highest positive influence, while the descriptors related to the unbalance between the centre of 
mass of a molecule and the barycenter of its hydrophobic regions (A – amphiphilic moment, 
ID1 – integy moment), partition coefficient of cyclohexane/water (LOGP c-Hex), and ratio of 
molecular volume and molecular surface (R) have the highest negative influence on the 
antiproliferative activity. Therefore, increase of H-bonding properties, hydrophobicity and 
flexibility, as well as decrease of unbalance in distribution of hydrophobic and hydrophilic 
regions in the molecule, should lead to increase in compound’s antiproliferative activity 
against all three studied cell lines. 
  
 
Figure 2. PLS coefficients of 3D-derived QSAR model: A) model 1 (H460), B) model 2 
(HCT 116)  and C) model 3 (MCF-7). Descriptors with the highest impact on the activity are 
labeled; list and description of all 128 VolSurf+ descriptors is given in the VolSurf+ manual
 
[15]. 
2.3. Biological Results and Discussion 
 
The antiproliferative activities of new 2-amino, 5-amino and 2,5-diamino substituted 
benzimidazo[1,2-a]quinolines were tested on human colon, breast and lung tumor cell lines 
(Table 1). Among 2-amino substituted benzimidazo[1,2-a]quinolines (5–9) three compounds 
strongly inhibited the growth of all cell lines. The most cytotoxic (IC50 < 1 M) were N-
methylpiperazinyl and dimethyl-piperazinyl substituted compounds 8 and 9. Comparing the 
activity of compounds with different lengths of amino side chains (5–7), it can be seen that 
the activity is reduced by the side chain length, possibly because the longer side chains 
increase the amphiphilic moment (A) and increase the unbalance in distribution of 
hydrophobic regions in the molecule. Since these properties are found by QSAR analysis as 
negatively correlated with the activities, their increase leads to decrease of antiproliferative 
activities.  In case of compounds 18, 19, and 20 the opposite effect of the side chain length on 
the activities was noticed because the position of the chain is different and in this case the 
longer aliphatic chain decreases the unbalance in distribution of hydrophobic regions in the 
molecule and has the opposite effect on the activity. Therefore, the activities of compounds 19 
and 20 are comparable to compounds 6 and 7 that bear the same side chains, while the activity 
of compound 5 is much higher than the activity of the compound 20. Among the most 
abundant group of 2,5-diamino substituted benzimidazo[1,2-a]quinolines, piperazinyl-
substituted compounds (36, 38, 39) showed the most pronounced antiproliferative activity, 
whereby dimethyl-piperazinyl substituted benzimidazo[1,2-a]quinoline (39) was the most 
active one. The most pronounced antiproliferative activity of above mentioned compounds 
could be due the presence of another N heteroatom which contributes to the additional 
interactions with potential biological targets. Interestingly, N,N-dimethyl substituted 
quaternary iodide salt 37 was completely inactive, similarly to previously published N,N-
dimethyl substituted quaternary iodide salt with amino substituent at position 5 on 
benzimidazo[1,2-a]quinoline skeleton. This is in agreement with QSAR analysis that 
identified the percentage of unionised species as negatively correlated descriptor with the 
activities against H460 and HCT 116 cell lines.  Piperidinyl and morpholinyl-substituted 
analogues 34, 35 showed moderate activity (IC50 10–20 M), while pyrrolydinyl-substituted 
analogue 33 showed pronounced activity on HCT 116 and MCF-7 cell lines. 2,5-diamino 
substituted derivatives with secondary amino side chains 23–27 showed moderate 
antiproliferative activity while disubstituted derivatives 30–32 with tertiary amino side chains 
showed decrease of antiproliferative activity which lead to the fact that secondary amine side 
chain is generally slightly preferred over tertiary amine side chain. Also, disubstituted 
derivatives 28 and 32 with the longest amino side chains did not show antiproliferative effect 
towards tested cell lines. In general, there was no significant difference in the sensitivity 
towards the tested compounds between the cell lines, which may indicate common 
mechanisms of action of new compounds. The only exception is compound 23, which showed 
less pronounced activity toward H460 cell line.  
 
Table 1. IC50 values (in μM) 
a 
Cell lines 
Compounds HCT116 MCF-7 H460 
5 0.8±0.2 0.7±0.4 2±0.8 
6 3±0.3 2±0.09 4±0.3 
7 5±0.3 5±0.6 5±2 
8 0.6±0.3 2±1 1±0.8 
9 0.3±0.08 0.6±0.2 0.5±0.04 
18 13±0.4 20±3 5±2 
19 5±1 4±0.5 2±0.5 
20 4±1 3±0.6 2±0.3 
21 3±0.2 3±0.3 4±0.6 
22 3±0.2 6±2 4±0.3 
23 7±3 2±1 ≥100 
24 7±1 5±0.8 4±1 
25
b
 ≥10 7±1 21±2 
26 2±0.2 2±0.6 3±0.2 
27 6±0.3 2±0.05 5±0.2 
28 >100 >100 >100 
30 16±4 22±3 25±2 
31 14±5 21±6 29±0.2 
32 >100 >100 >100 
33 2±0.5 2±0.6 12±1 
34 11±3 10±3 15±2 
35 11±5 9±1 18±8 
36 1.5±0.3 1±0.001 4±0.6 
37 >100 >100 >100 
38 2±0.5 4±1 3±0.5 
39 0.4±0.09 1±0.2 0.8±0.3 
a
 IC50; the concentration that causes 50% growth inhibition 
b
 The highest tested concentration was 10 µM.  
 
2.4. DNA Binding Properties 
As a first approach to evaluate drug/DNA binding, we challenged compounds 23, 24, 
26 and 30 to 37 for double strand DNA stabilization of calf thymus-DNA (CT-DNA) using 
DNA melting temperature experiments. As part of their potential DNA interaction, the 
temperature for which half of the double strand DNA is melted to single stand DNA (Tm) 
may increase upon DNA binding of the tested compound (positive Tm) suggesting 
stabilization of the DNA helix, or, rarely decrease, evidencing DNA denaturation by the 
evaluated compound (negative Tm).  
From this series, only compounds 36 and 37 presented potent DNA helix stabilization 
whereas none of the other tested compounds changed the intrinsic melting temperature of CT-
DNA. For compound 36, the Tm values were 15.9 °C and 20.1 °C at 1:2 and 1:4 drug/DNA 
ratios, respectively. By contrast, compound 37 induced-stabilization of the DNA helix 
required more than 24 °C at 1:4 drug/DNA ratio to achieve denaturation of half of the DNA 
(Tm), a value that could not be determined using higher drug/DNA ratios since less than half 
of the DNA denaturation could be achieved using temperature as high as 100 °C, suggesting 
very strong DNA stabilization upon binding of 37 to DNA. Those two DNA binding 
compounds were further evaluated using spectrophotometric analysis. 
First, DNA binding propensity of  36 and 37 was underlined using UV/Visible spectra 
measurement evidencing the modification of the absorption spectra of 36 (Figure 3A) or 37 in 
the presence of increasing concentrations of CT-DNA with hypochromic and bathochromic 
effects, a spectral modification frequently associated with DNA intercalation. 
However, spectral changes did not revealed any isosbestic point (typically arguing for single 
binding mode), suggesting that the mode of binding of the compounds to the DNA helix is 
rather a complex binding. In parallel, the intrinsic fluorescent properties of the compounds 
were also evaluated in the presence of increasing CT-DNA/compound ratios. Fluorescent 
measurement evidenced an increase in the fluorescent properties of compound 36 (Figure 3B). 
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Figure 3. A) UV/Vis titration of compound 36 with CT-DNA, B) Fluorimetric titration of 
compound 36 with CT-DNA 
 
In order to get an insight in the binding mode of 36 and 37, two approaches were used: 
circular dichroism spectra analysis and topoisomerase I-induced DNA relaxation. The first 
approach is based on the difference on the absorbance between right and left orientated light 
at a wavelength from 230 to 530 nm. The absence of intrinsic CD of 36 and 37 was validated 
using the highest evaluated dose (60 µM, Figure 4, dashed lines). Upon binding of either 36 
or 37 on CT-DNA, the intrinsic CD of CT-DNA (50 µM, pointed lines) was changed with (i) 
a decrease of the intensity of the positive intrinsic CD of CT-DNA at 275 nm (suggesting 
modifications in the base stacking and/or the ellipticity of the DNA helix) and (ii) the 
appearance of a new negative induced circular dichroic (ICD) signal from 290 to 440 nm 
corresponding to the absorption bands of either compounds 36 or 37 (suggesting the 
intercalation of the planar chromophore between adjacent base pairs of the DNA, thus 
creating a new dichroic signal). Both changes are dependent on the compounds concentration 
(top to bottom).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Circular dichroism spectra. CT-DNA (50 µM of base pairs) was incubated alone 
(dashed bold lines) with increasing concentrations of 36 or 37 from 1 to 60 (full bold lines) 
µM (top to bottom). Pointed bold lines correspond to the CD spectra of the compound alone 
(60 µM).  
In order to comfort the DNA intercalation profile of 36 and 37 in comparison with other 
derivatives, we used the property of the DNA topoisomerase I enzyme to resolve the 
constraints of a negatively supercoiled circular DNA and to generate positively supercoiled 
circular DNA generated upon intercalation between adjacent base pairs [16]. Intercalation 
between adjacent base pairs lengthens the DNA helix, diminishes the angle of rotation 
between each base pair and thus induces major constraints to the DNA structure. 
Topoisomerase I enzyme resolves the constraints that are generated upon negative 
supercoiling of the plasmid DNA when produced in bacteria (Sc) (Figure 5). Topoisomerase I 
thus generates different DNA topoisomers (Topo) corresponding to different number of 
released supercoils in the circular plasmid and up to fully relaxed circular DNA (Rel). 
Blockade of topoisomerase I re-ligation step by poison drugs such as camptothecin (CPT) 
results in the generation of nicked plasmid (Nck) that is only opened on one strand whereas 
DNA intercalation is associated with the formation of progressive positive supercoiled 
plasmid with each topoisomers being more difficult to assign individually due to binding of 
the compounds that reduces DNA migration within the agarose gel, as seen with 36 and 37 in 
Figure 5. This experiment confirms the DNA intercalation propensity of 36 and 37 but not the 
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other evaluated non DNA binders. This DNA intercalation is not associated with 
topoisomerase I poisoning effect of 36 and 37 as demonstrated by the lack of increase in the 
intensity of the nicked form (Nck) of the DNA. Such intercalation process is not associated 
with sequence selective binding as evaluated using DNase I footprinting experiments of 
increasing concentrations of either 36 or 37 (data not shown). 
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Figure 5. Topoisomerase I-induced DNA relaxation. The pUC19 supercoiled plasmid 
(“DNA”) was incubated with topoisomerase I (“0”) alone or in the presence of the indicated 
concentrations (µM) of compounds as specified on the top of the lanes. Rel, relaxed DNA; 
Nck, nicked DNA; Topo, topoisomers; Sc, supercoiled DNA. 
 
Compounds 33 and 23 presented a small increase of the band corresponding to the 
relaxed/nicked form. However, only compound 33 presented a very weak Topoisomerase I 
poisoning activity as confirmed upon migration in ethidium bromide containing agarose gels 
(see the weak increase in the nicked form using 100 µM as the highest drug concentration) 
whereas no poisoning activity was evidenced using compound 23 (Figure 6).  
                   
Figure 6. Topoisomerase I poisoning effects of compounds 33 and 23. Native supercoiled 
pUC19 plasmid DNA (lanes “DNA”) was incubated with topoisomerase I in the absence 
(lanes “Topo I”) or presence of increasing concentrations of compounds 33 and 23 and the 
reference drugs camptothecin (CPT). DNA samples were separated under electrophoresis on 
an ethidium bromide containing 1% agarose gel. The gels were photographed under UV light. 
Sc, supercoiled; Rel, relaxed; Nck; nicked; Lin, linear. 
 
3. Conclusion 
Herein we present the synthesis of 2-amino, 5-amino and 2,5-diamino substituted 
benzimidazo[1,2-a]quinolines with different type and length of amino side chains placed on 
either one or two positions on quinoline nuclei with potential chemotherapeutic activities. 
Amino-substituted compounds were synthesized by uncatalyzed microwave assisted 
amination from corresponding chloro or fluoro substituted precursors. The antiproliferative 
activities tested on human colon, breast and lung tumor cell lines ranged from moderate to 
very strong. 2-amino-subsituted analogues demonstrated stronger antiproliferative activity 
compared to 5-amino, or 2,5-diamino substituted derivatives. In general, N-methyl or 3,5-
dimethylpiperazinyl substituted analogues were the most active ones (submicromolar IC50 
concentrations), while derivatives with long and/or branched side chains were less active 
(mono-substituted analogues) or completely inactive (di-substituted analogues). 3D-QSAR 
analysis showed that the molecular properties with the highest positive and the highest 
negative influence on antiproliferative activity are common for all three studied cell lines. The 
increase compound’s H-bonding properties, hydrophobicity and flexibility, as well as the 
decrease of unbalance in distribution of hydrophobic and hydrophilic regions in the molecule, 
should increase the compound’s antiproliferative activity against all three studied cell lines. 
By evaluating some compounds in both series for their DNA binding propensities, we 
evidenced that only two of those selected compounds were potent DNA binding agents, 
associated with strong DNA helix stabilization (as evidenced using melting temperature 
studies) and intercalative mode of DNA interaction (Figures 4 and 5). This DNA binding is 
not associated with sequence selective binding (data not shown). The DNA intercalation 
process does not correlate with their cytotoxic effects evaluated on both colon (HCT116), 
breast (MCF-7) and lung (H460) carcinoma since if the piperazinyl compound 36 as a potent 
cytotoxic effect in all cell lines (1.5, 1 and 4 µM, respectively), the N,N-dimethyl substituted 
quaternary iodide salt 37 is totally inactive (>100µM) in the three cellular models which is in 
agreement with the QSAR analysis. 
 
4. Experimental part 
4.1. General methods 
All chemicals and solvents were purchased from commercial suppliers Aldrich and 
Acros. Melting points were recorded on SMP11 Bibby and Büchi 535 apparatus. All NMR 
spectra were measured in DMSO-d6 solutions using TMS as an internal standard. The 
1
H and 
13
C NMR spectra were recorded on a Varian Gemini 300 or Varian Gemini 600 at 300, 600 
and 150 and 75 MHz, respectively. Chemical shifts are reported in ppm (δ) relative to TMS. 
All compounds were routinely checked by TLC with Merck silica gel 60F-254 glass plates. 
Microwave-assisted synthesis was performed in a Milestone start S microwave oven using 
quartz cuvettes under the pressure of 40 bar. Mass spectra were recorded on an Agilent 1200 
series LC/6410 QQQ instrument. The electronic absorption spectra were recorded on Varian 
Cary 50 spectrometer using quartz cuvette (1 cm). Elemental analysis for carbon, hydrogen 
and nitrogen were performed on a Perkin-Elmer 2400 elemental analyzer. Where analyses are 
indicated only as symbols of elements, analytical results obtained are within 0.4% of the 
theoretical value.   
 
 
 
 4.2. Synthesis of 2-amino substituted benzimidazo[1,2-a]quinolines 
4.2.1. 2-(2-Benzimidazolyl)-3-(2-chloro-4-fluorophenyl)acrylonitrile 3. Compound 3 was 
prepared from 2 (1.00 g,  6.37 mmol) and 2-chloro-4-fluorobenzaldehyde 1 (1.00 g,  6.31 
mmol)  in absolute ethanol (7 ml) after refluxing for 2 h and recrystallization from ethanol to 
yield 1.41 g (75%) of slightly yellow crystals; m.p. 234–237 °C; 1H NMR (300 MHz, DMSO-
d6): /ppm= 13.31 (s, 1H, NHbenzim.), 8.46 (s, 1H, Harom.), 8.21 (dd, 1H, J1=6.22 Hz, J2=9.07 
Hz, Harom.), 7.74 (dd, 1H, J1=2.69 Hz, J2=8.82 Hz, Harom.), 7.66 (bs, 2H, Hbenzim.), 7.51 (dt, 1H, 
J1=2.81 Hz, J2=8.07 Hz, Hbenzim.), 7.30 (bs, 1H, Hbenzim.); 
13
C NMR (75 MHz, DMSO-d6): 
/ppm= 163.77 (s, JCF=251.09 Hz), 147.05 (s), 143.73 (s), 140.69 (d), 135.62 (s, JCF=7.20 
Hz), 135.32 (s), 131.93 (d, JCF=9.64 Hz), 128. 41 (s, JCF=3.52 Hz), 124.54 (d), 122.97 (d), 
119.96 (d), 119.17 (d, JCF=25.36 Hz), 115.80 (s), 115.81 (d, JCF=21.71 Hz), 112.23 (d), 
107.16 (s); Found: C, 64.81; H, 3.04; N, 6.40. Calc. for C17H12N4: C, 64.55; H, 3.05; N, 
6.38%; MS (ESI): m/z= 298.1 ([M+1]
+
). 
4.2.2. 2-Fluorobenzimidazo[1,2-a]quinoline-6-carbonitrile 4. Compound 3 (0.50 g, 1.68 
mmol) was dissolved in 4 ml of sulfolane and reaction mixture was heated for 25 minutes at 
280 °C. The cooled mixture was poured into water (15 ml) and the resulting product was 
filtered off and recrystallizated from ethanol (450 ml) to obtain a yellow powder (0.32 g, 
72%); m.p. 250–254 °C; 1H NMR (300 MHz, DMSO-d6): /ppm= 8.77 (s, 1H, Harom.), 8.71 
(d, 1H, J=8.25 Hz, Harom.), 8.52 (dd, 1H, J1=2.10 Hz, J2=10.89 Hz, Harom.), 8.20 (dd, 1H, 
J1=6.44 Hz, J2=8.42 Hz, Harom.), 7.99 (d, 1H, J=8.21 Hz, Harom.), 7.61 (t, 1H, J=6.82 Hz, 
Harom.), 7.58–7.51 (m, 2H, Harom.); 
13
C NMR (DMSO-d6): /ppm= 164.67 (s, JCF=251.84 Hz), 
144.35 (s), 143.63 (s), 140.01 (d), 136.85 (s, JCF=12.50 Hz), 133.75 (d, JCF=11.01 Hz), 130.22 
(s), 125.28 (d), 123.70 (d), 120.13 (d), 118.14 (s, JCF=2.28 Hz), 115.26 (s), 114.83 (d), 113.82 
(d, JCF=23.37 Hz), 103.08 (d, JCF=27.68 Hz), 100.35 (s); Found: C, 73.27; H, 3.10; N, 16.05. 
Calc. for C17H12N4: C, 73.56; H, 3.09; N, 16.00%; MS (ESI): m/z= 262.1 ([M+1]
+
). 
4.2.3. General method for preparation of compounds 5–9 
Compounds 5–9 were prepared using microwave irradiation, at optimized power and reaction 
time, from compound 4 in acetonitrile (10 mL) with excess of added corresponding amine. 
After cooling, the reaction mixture was filtered off and resulting product was separated by 
column chromatography on SiO2 using dichlormethane/methanol as eluent.  
4.2.3.1. 2-N-i-propylaminobenzimidazo[1,2-a]quinoline-6-carbonitrile 5. Compound 5 was 
prepared using above described method from 4 (100 mg, 0.38 mmol) and i-propylamine (0.15 
mL, 1.76 mmol) after 6 h of irradiation to yield 46 mg (43%) of yellow crystals; m.p. 230–
233 °C. 
1
H NMR (300 MHz, DMSO-d6): /ppm8.51 (d, 1H, J=8.10 Hz, Harom.), 8.46 (s, 1H, 
Harom.), 7.94 (dd, 1H, J1=1.28 Hz, J2=7.50 Hz, Harom.), 7.81 (d, 1H, J=8.85 Hz, Harom.), 7.77 (s, 
1H, Harom.), 7.58 (dt, 1H, J1=1.28 Hz, J2=7.30 Hz, Harom.), 7.52 (dt, 1H, J1=1.28 Hz, J2=7.30 
Hz, Harom.), 7.27 (d, 1H, J=7.56 Hz, NH), 6.91 (dd, 1H, J1=1.75 Hz, J2=8.85 Hz, Harom.), 3.98–
3.87 (m, 1H, CH), 1.28 (d, 6H, J=6.59 Hz, CH3); 
13
C NMR (150 MHz, DMSO-d6): /ppm= 
152.97 (s), 145.90 (s), 144.18 (d), 140.12 (d), 138.11 (s), 132.93 (d), 130.40 (s), 124.70 (d), 
122.40 (d, 2C), 119.56 (d), 116.76 (s), 114.33 (d, 2C), 111.04 (s), 91.92 (s), 43.36 (d), 22.24 
(q, 2C); Found: C, 75.73; H, 5,52; N, 18,75. Calc. for C19H16N4: C, 75.98; H, 5.37; N, 
18.65%; MS (ESI): m/z= 301.2 ([M+1]
+
).  
4.2.3.2. 2-N-i-pentylaminobenzimidazo[1,2-a]quinoline-6-carbonitrile 6. Compound 6 was 
prepared using above described method from 4 (80 mg, 0.30 mmol) and isopentylamine (0.25 
mL, 2.15 mmol) after 5 h of irradiation to yield 29 mg (29%) of yellow crystals; m.p. 200–
205 °C. 
1
H NMR (300 MHz, DMSO-d6): /ppm= 8.50 (d, 1H, J=8.36 Hz, Harom.), 8.46 (s, 1H, 
Harom.), 7.94 (dd, 1H, J1=1.40 Hz, J2=7.77 Hz, Harom.), 7.80 (d, 1H, J=8.93, Harom.), 7.74 (s, 
1H, Harom.), 7.57 (dt, 1H, J1=1.00 Hz, J2=7.39 Hz, Harom.), 7.51 (dt, 1H, J1=1.28 Hz, J2=7.52 
Hz, Harom.), 7.31 (t, 1H, J=5.17 Hz, NH), 6.90 (dd, 1H, J1=1.70 Hz, J2=8.85 Hz, Harom.), 3.32 
(q, 2H, J=7.08 Hz, CH2), 1.80–1.75 (m, 1H, CH), 1.57 (q, 2H, J=6.85 Hz, CH2), 0.98 (d, 6H, 
J=6.54 Hz, CH3); 
13
C NMR (150 MHz, DMSO-d6): /ppm= 153.84 (s), 145.92 (s), 144.21 (s), 
140.10 (d), 138.11 (s), 132.81 (d), 130.40 (s), 124.34 (d), 122.34 (d), 119.56 (d), 116.73 (s), 
114.32 (d), 111.16 (s), 92.00 (s), 40.60 (t), 37.28 (t), 25.23 (d), 22.37 (q, 2C); Found: C, 
76.93; H, 5.99; N, 17.08. Calc. for C21H20N4: C, 76.80; H, 6.14; N, 17.06%; MS (ESI): m/z= 
329.3 ([M+1]
+
). 
4.2.3.3. 2-N-hexylaminobenzimidazo[1,2-a]quinoline-6-carbonitrile 7. Compound 7 was 
prepared using above described method from 4 (90 mg, 0.34 mmol) and hexylamine (0.24 
mL, 1.20 mmol) after 3 h of irradiation to yield 60 mg (54%) of yellow crystals; m.p. 97–104 
°C. 
1
H NMR (600 MHz, DMSO-d6): /ppm= 8.48 (d, 1H, J=8.28 Hz, Harom.), 8.43 (s, 1H, 
Harom.), 7.92 (d, 1H, J=7.62 Hz, Harom.), 7.78 (d, 1H, J=8.76 Hz, Harom.), 7.70 (s, 1H, Harom.), 
7.56 (t, 1H, J=7.62 Hz, Harom.), 7.50 (dt, 1H, J1=1.06 Hz, J2=7.72 Hz, Harom.), 7.31 (t, 1H, 
J=5.10 Hz, NH), 6.88 (dd, 1H, J1=1.74 Hz, J2=8.76 Hz, Harom.), 1.66 (p, 2H, J=7.26 Hz, CH2), 
1.44 (p, 2H, J=7.36 Hz, CH2), 1.36–1.31 (m, 4H, CH2), 0.88 (t, 3H, J=7.08 Hz, CH3); 
13
C 
NMR (150 MHz, DMSO-d6): /ppm= 153.87 (s), 145.85 (s), 144.00 (s), 140.14 (d), 130.34 
(s), 124.73 (d), 122.38 (d, 2C), 119.45 (d), 116.72 (s), 114.34 (d, 2C), 111.14 (s), 91.61 (s), 
42.40 (t), 31.06 (t), 28.36 (t), 26.27 (t), 22.68 (t), 13.90 (q); Found: C, 76.98; H, 6.28; N, 
16.74. Calc. for C22H22N4: C, 77.16; H, 6.48; N, 16.36%; MS (ESI): m/z= 343.2 ([M+1]
+
). 
4.2.3.4. 2-[N-(4-N-methylpiperazinyl)]benzimidazo[1,2-a]quinoline-6-carbonitrile 8. 
Compound 8 was prepared using above described method from 4 (90 mg, 0.34 mmol) and 4-
N-methylpiperazine (0.10 mL, 0.90 mmol) after 3 h of irradiation to yield 65 mg (56%) of 
yellow crystals; m.p. 267–273 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.56 (s, 1H, 
Harom.), 8.55 (d, 1H, J=7.68 Hz, Harom.), 7.94 (dd, 1H, J1=1.36 Hz, J2=7.48 Hz, Harom.), 7.91 (d, 
1H, J=9.15 Hz, Harom.), 7.80 (d, 1H, J=1.05 Hz, Harom.), 7.59 (t, 1H, J=6.78 Hz, Harom.), 7.54 
(dt, 1H, J1=1.42 Hz, J2=7.34 Hz, Harom.), 7.33 (dd, 1H, J1=1.72 Hz, J2=9.25 Hz, Harom.), 3.61 
(t, 4H, J=4.80 Hz, CH2), 2.54 (t, 4H, J=5.09 Hz, CH2), 2.27 (s, 3H, CH3); 
13
C NMR (75 MHz, 
DMSO-d6): /ppm= 154.61 (s), 146.15 (s), 144.57 (s), 140.34 (d), 138.60 (s), 132.83 (d), 
130.78 (s), 125.38 (d), 123.46 (d), 120.17 (d), 116.87 (s), 115.35 (d), 113.02 (d), 112.84 (s), 
98.13 (d), 94.88 (s), 54.79 (t, 2C), 47.14 (t, 2C), 46.16 (t, 2C); Found: C, 73.98; H, 5.71; N, 
20.31. Calc. for C21H19N5: C, 73.88; H, 5.61; N, 20.51%; MS (ESI): m/z= 342.2 ([M+1]
+
). 
4.2.3.5. 2-[N-(3,5-dimethylpiperazinyl)]benzimidazo[1,2-a]quinoline-6-carbonitrile 9. 
Compound 9 was prepared using above described method from 4 (90 mg, 0.34 mmol) and 
2,6-dimethylpiperazine (0.150 g, 1.30 mmol) after 6 h of irradiation to yield 39 mg (33%) of 
yellow powder; m.p. 263–268 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.47 (s, 1H, 
Harom.), 8.43 (dd, 1H, J1=1.19Hz, J2=7.13 Hz, Harom.), 7.94 (dd, 1H, J1=1.41 Hz, J2=7.56 Hz, 
Harom.), 7.84 (d, 1H, J=9.12 Hz, Harom.), 7.68 (s, 1H, Harom.), 7.58 (dt, 1H, J1=1.21, J2=6.59 Hz, 
Harom.), 7.53 (dt, 1H, J1=1.28 Hz, J2=6.69 Hz, Harom.), 7.27 (dd, 1H, J1=1.66 Hz , J2=9.13 Hz, 
Harom.), 4.01 (d, 2H, J=10.53 Hz, CH2), 2.95–2,90 (m, 2H, CH), 2.55 (d, 2H, J=11.70 Hz, 
CH2), 1.13 (d, 6H, J=6.21 Hz, CH3); 
13
C NMR (75 MHz, DMSO-d6): /ppm= 154.27 (s), 
146.15 (s), 144.56 (s), 140.18 (d), 138.57 (s), 132.74 (d), 130.72 (s), 125.29 (d), 123.38 (d), 
120.13 (d), 116.92 (s), 115.14 (d), 112.93 (d), 112.53 (s), 97.85 (d), 94.51 (s), 53.67 (t, 2C), 
50.61 (d, 2C), 19.56 (q, 2C); Found: C, 74.40; H, 6.08; N, 19.52. Calc. for C22H21N5: C, 
74.34; H, 5.96; N, 19.70%; MS (ESI): m/z= 356.3 ([M+1]
+
). 
 
 
4.3. Synthesis of 5-amino substituted benzimidazo[1,2-a]quinolines 
4.3.1. 2-(2-benzimidazolyl)-3-keto-(2-chlorophenyl)acrylonitrile 12 [14].
 
A solution of 1.57 g (10.00 mmol) 2-cyanomethylbenzimidazole 2 and 1.33 mL (10.50 mmol) 
2-chloro-benzoylchloride 10 in pyridine (10 mL) was refluxed for 2 h. The cooled mixture 
was poured into water (100 mL) and the resulting product was filtered off and recrystallized 
from ethanol to obtain a brown powder (1.31 g, 44%); m.p. >300 °C. 
1
H NMR (300 MHz, 
DMSO-d6): /ppm= 13.09 (bs, 2H, NH), 7.59–7.50 (m, 3H, Harom.), 7.48–7.42 (m, 3H, Harom.), 
7.32–7.28 (m, 2H, Harom.); 
13
C NMR (75 MHz, DMSO-d6): ppm= 185.01 (s), 151.04 (s), 
140.93 (s), 130.88 (s, 2C), 130.80 (d), 130.02 (s), 129.91 (d), 128.91 (d), 127.51 (d), 124.09 
(d, 2C), 120.29 (s), 112.71 (d, 2C), 67.62 (s). 
 4.3.2. 5-ketobenzimidazo1,2-aquinoline-6-carbonitrile 14 [14]. 
A solution of 0.50 g (1.69 mmol) 2-(2-benzimidazolyl)-3-keto-(2-chlorophenyl)acrylonitrile 
12 and 0.44 g t-KOBu in DMF (6 mL) was refluxed for 3 h. After cooling, the reaction 
mixture was evaporated under vacuum and dissolved in water (50 mL). Resulting product was 
filtered off and recrystallized from ethanol to obtain a white powder (0.25 g, 57%); m.p. >300 
°C. 
1
H NMR (300 MHz, DMSO-d6): /ppm= 8.42 (d, 1H, J=8.37 Hz, Harom.), 8.25 (dd, 1H, 
J1=1.52 Hz, J2=7.82 Hz, Harom.), 8.20 (d, 1H, J=8.10 Hz, Harom.), 7.71 (dt, 1H, J1=1.68 Hz, 
J2=7.95 Hz, Harom.), 7.47 (d, 1H, J=7.83 Hz, Harom.), 7.38 (t, 1H, J=7.49 Hz, Harom.), 7.23 (t, 
1H, J=7.56 Hz, Harom.), 7.10 (t, 1H, J=7.56 Hz, Harom.); 
13
C NMR (150 MHz, DMSO-d6): 
ppm= 172.34 (s), 153.85 (s), 145.83 (s), 136.33 (s), 131.21 (s), 130.97 (d), 126.39 (d), 
124.61 (s), 122.83 (d), 122.56 (d), 120.55 (s), 118.73 (d), 116.36 (d), 114.85 (d), 112.21 (d). 
4.3.3. 5-chlorobenzimidazo1,2-aquinoline-6-carbonitrile 16 [14]. 
A solution of 0.20 g (0.77 mmol) 5-ketobenzimidazo1,2-aquinoline-6-carbonitrile and 0.08 
g (0.39 mmol) PCl5 in POCl3 (4 mL) was refluxed for 2 h. After cooling, the reaction mixture 
was evaporated under vacuum and dissolved in water (10 mL). Resulting product was filtered 
off and washed with water to obtain a yellow powder (0.15 g, 70%); m.p. >300 °C. 
1
H NMR 
(300 MHz, DMSO-d6): /ppm= 8.96 (d, 1H, J=8.37 Hz, Harom.), 8.79 (dd, 1H, J1=2.16 Hz, 
J2=6.46 Hz, Harom.), 8.42 (dd, 1H, J1=1.39 Hz, J2=8.20 Hz, Harom.), 8.13 (dt, 1H, J1=1.52 Hz, 
J2=7.89 Hz, Harom.), 8.06 (dd, 1H, J1=2.18 Hz, J2=6.10 Hz, Harom.), 7.81 (t, 1H, J=7.54 Hz, 
Harom.), 7.69–7.58 (m, 2H, Harom.); 
13
C NMR (150 MHz, DMSO-d6): ppm= 144.64 (s), 
142.98 (s), 136.17 (s), 135.04 (d), 131.08 (s), 128.32 (d), 126.18 (d), 125.86 (d), 124.50 (d), 
120.91 (d), 119.84 (s), 116.79 (d), 115.28 (d), 113.59 (s), 103.11 (s).  
4.3.4. General method for preparation of compounds 18–22 
Compounds 18–22 were prepared using microwave irradiation, at optimized reaction 
time with power 800 W and 40 bar pressure, from compound 16 in acetonitrile (10 mL) with 
excess of added corresponding amine. After cooling, the reaction mixture was filtered off and 
resulting product was separated by column chromatography on SiO2 using 
dichloromethane/methanol as eluent.  
4.3.4.1. 5-N-i-propylaminobenzimidazo[1,2-a]quinoline-6-carbonitrile 18. 
Compound 18 was prepared using above described method from 16 (100 mg, 0.38 mmol) and 
i-propylamine (0.10 mL, 1.12 mmol) after 2 h of irradiation to yield 42 mg (39%) of white 
powder; m.p. 260–263 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.66 (d, 1H, J=8.08 Hz, 
Harom.), 8.55 (dd, 1H, J1=0.92 Hz, J2=7.76 Hz, Harom.), 8.43 (d, 1H, J=8.08 Hz, Harom.), 7.93 
(dt, 1H, J1=0.92 Hz, J2=8.12 Hz, Harom.), 7.75 (dd, 1H, J1=0.60 Hz, J2=7.86 Hz, Harom.), 7.59 
(t, 1H, J=7.60 Hz, Harom.), 7.55 (t, 1H, J=6.81 Hz, NH), 7.42 (t, 1H, J=7.50 Hz, Harom.), 7.33 
(dt, 1H, J1=1.17 Hz, J2=7.40 Hz, Harom.), 4.90–4.79 (m, 1H, CH), 5.99 (d, 6H, J=6.68 Hz, 
CH3); 
13
C NMR (150 MHz, DMSO-d6): ppm= 149.15 (s), 148.99 (s), 144.67 (s), 135.05 (s), 
132.96 (d), 130.79 (s), 124.78 (d), 124.13 (d), 123.88 (d), 121.28 (d), 118.36 (d), 117.53 (s), 
116.54 (s), 116.14 (d), 113.62 (d), 71.84 (s), 45.87 (d), 23.00 (q, 2C); Found: C, 75.77; H, 
5.69; N, 18.54. Calc. for C19H16N4: C, 75.98; H, 5.37; N, 18.65%; MS (ESI): m/z= 301.2 
([M+1]
+
). 
4.3.4.2. 5-N-i-pentylaminobenzimidazo[1,2-a]quinoline-6-carbonitrile 19. 
Compound 19 was prepared using above described method from 16 (50 mg, 0.18 mmol) and 
i-pentylamine (0.11 mL, 0.90 mmol) after 2 h of irradiation to yield 9 mg (15%) of white 
powder; m.p. 105–108 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.67 (d, 1H, J=8.65 Hz, 
Harom.), 8.49 (d, 1H, J=8.35 Hz, Harom.), 8.43 (d, 1H, J=8.35 Hz, Harom.), 8.11 (t, 1H, J=5.68 
Hz, NH), 7.93 (t, 1H, J=7.46 Hz, Harom.), 7.74 (d, 1H, J=7.76 Hz, Harom.), 7.59 (t, 1H, J=7.76 
Hz, Harom.), 7.41 (t, 1H, J=7.46 Hz, Harom.), 7.33 (t, 1H, J=7.61 Hz, Harom.), 3.91 (q, 2H, J=6.86 
Hz, CH2), 1.67–1.58 (m, 1H, CH), 1.43 (q, 2H, J=7.16 Hz, CH2), 0.88 (q, 6H, J=6.27 Hz, 
CH3); 
13
C NMR (150 MHz, DMSO-d6): ppm= 149.95 (s), 149.03 (s), 144.67 (s), 135.02 (s), 
132.95 (d), 130.81 (s), 124.40 (d), 124.28 (d), 123.88 (d), 121.27 (d), 118.34 (d), 117.60 (s), 
116.57 (s), 116.25 (d), 113.62 (d), 71.46 (s), 42.59 (t), 37.21 (t), 22.39 (d), 22.09 (q, 2C); 
Found: C, 77.05; H, 6.02; N, 16.93. Calc. for C21H20N4: C, 76.80; H, 6.14; N, 17.06%; MS 
(ESI): m/z= 329.3 ([M+1]
+
). 
4.3.4.3. 5-N-hexylaminobenzimidazo[1,2-a]quinoline-6-carbonitrile 20. 
Compound 20 was prepared using above described method from 16 (100 mg, 0.36 mmol) and 
hexylamine (0.20 mL, 1.52 mmol) after 3 h of irradiation to yield 56 mg (48%) of yellow 
powder; m.p. 121–125 °C. 1H NMR (600 MHz, DMSO-d6): /ppm= 8.65 (d, 1H, J=8.34 Hz, 
Harom.), 8.44 (dd, 1H, J1=0.84 Hz, J2=8.37 Hz, Harom.), 8.41 (d, 1H, J=8.27 Hz, Harom.), 8.07 (t, 
1H, J=5.58 Hz, NH), 7.90 (dt, 1H, J1=0.87 Hz, J2=7.73 Hz, Harom.), 7.73 (d, 1H, J=7.80 Hz, 
Harom.), 7.57 (t, 1H, J=7.59 Hz, Harom.), 7.40 (t, 1H, J=7.47 Hz, Harom.), 7.32 (dt, 1H, J1=0.93 
Hz, J2=7.73 Hz, Harom.), 3.86 (q, 2H, J=6.58 Hz, CH2), 1.78 (p, 2H, J=7.19 Hz, CH2), 1.42 (p, 
2H, J=7.28 Hz, CH2), 1.31 (m, 4H, CH2), 0.86 (t, 3H, J=7.08 Hz, CH3); 
13
C NMR (150 MHz, 
DMSO-d6): ppm= 149.88 (s), 149.00 (s), 144.65 (s), 135.00 (s), 132.11 (d), 130.79 (s), 
124.31 (d), 124.25(d), 123.86 (d), 121.25 (d), 118.32 (d), 117.54 (s), 116.51 (s), 116.22 (d), 
113.59 (d), 71.42(s), 44.05 (t), 30.92 (t), 29.37 (t), 25.56 (t), 21.96 (t), 13.60 (q); Found: C, 
77.36; H, 6.18; N, 16.46. Calc. for C22H22N4: C, 77.16; H, 6.48; N, 16.36%; MS (ESI): m/z= 
343.2 ([M+1]
+
). 
4.3.4.4. 5-[N-(4-N-methylpiperazinyl)]benzimidazo[1,2-a]quinoline-6-carbonitrile 21. 
Compound 21 was prepared using above described method from 16 (100 mg, 0.36 mmol) and 
4-N-methylpiperazine (0.10 mL, 0.90 mmol) after 3 h of irradiation to yield 53 mg (43%) of 
yellow powder; m.p. 253–257 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.77 (d, 1H, 
J=8.46 Hz, Harom.), 8.59 (d, 1H, J=7.86 Hz, Harom.), 8.17 (dd, 1H, J1=0.78 Hz, J2=8.04 Hz, 
Harom.), 7.95 (dt, 1H, J1=0.95 Hz, J2=7.38 Hz, Harom.), 7.89 (dd, 1H, J1=1.08 Hz, J2=7.44 Hz, 
Harom.), 7.63 (t, 1H, J=7.70 Hz, Harom.), 7.52 (t, 1H, J=7.20 Hz, Harom.), 7.46 (dt, 1H, J1=1.06 
Hz, J2=7.69 Hz, Harom.), 3.63 (t, 4H, J=4.58 Hz, CH2), 2.66 (t, 4H, J=4.51 Hz, CH2), 2.33 (s, 
3H, CH3); 
13
C NMR (150 MHz, DMSO-d6): ppm= 157.28 (s), 146.94 (s), 144.31 (s), 136.10 
(s), 133.18 (d), 130.63 (d), 127.53 (d), 124.65 (d), 124.60 (d), 122.58 (d), 119.46 (s), 119.41 
(d), 116.33 (d), 115.91 (s), 114.26 (d), 89.09 (s), 54.88 (t, 2C), 52.10 (t, 2C), 45.77 (q); 
Found: C, 73.76; H, 5.81; N, 20.40. Calc. for C21H19N5: C, 73.88; H, 5.61; N, 20.51%; MS 
(ESI): m/z= 342.2 ([M+1]
+
). 
4.3.4.5. 5-[N-(3,5-dimethylpiperazinyl)]benzimidazo[1,2-a]quinoline-6-carbonitrile 22. 
Compound 22 was prepared using above described method from 16 (100 mg, 0.36 mmol) and 
2,6-dimethylpiperazine (0.100 g, 0.87 mmol) after 3 h of irradiation to yield 60 mg (47%) of 
yellow powder; m.p. 247–250 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.73 (d, 1H, 
J=8.46 Hz, Harom.), 8.56 (d, 1H, J=7.86 Hz, Harom.), 8.14 (d, 1H, J=8.19 Hz, Harom.), 7.93 (t, 
1H, J=7.88 Hz, Harom.), 7.87 (d, 1H, J=7.86 Hz, Harom.), 7.61 (t, 1H, J=7.53 Hz, Harom.), 7.51 (t, 
1H, J=7.45 Hz, Harom.), 7.44 (t, 1H, J=7.63 Hz, Harom.), 3.60 (d, 2H, J=11.16 Hz, CH2), 3.10 
(m, 2H, CH), 3.04 (d, 2H, J=11.11 Hz, CH2), 1.05 (d, 6H, J=5.97 Hz, CH3); 
13
C NMR (150 
MHz, DMSO-d6): ppm= 157.06 (s), 147.13 (s), 144.36 (s), 136.14 (s), 133.08 (d), 130.54 
(s), 127.53 (d), 127.68 (d), 124.60 (d), 124.45 (d), 122.47 (d), 119.49 (s), 119.41 (s), 119.33 
(d), 116.30 (d), 115.99 (s), 114.19 (d), 100.41 (s), 59.01 (t, 2C), 50.85 (d, 2C), 39.24 (q, 2C);  
Found: C, 74.18; H, 6.16; N, 19.60. Calc. for C22H21N5: C, 74.34; H, 5.96; N, 19.70%; MS 
(ESI): m/z= 356.3 ([M+1]
+
). 
4.4. Synthesis of 2,5-diamino substituted benzimidazo[1,2-a]quinolines 
4.4.1. 2-(2-benzimidazolyl)-3-keto-(4-fluoro-2-chlorophenyl)acrylonitrile 13.
 
A solution of 1.63 g (10.40 mmol) 2-cyanomethylbenzimidazole 2 and 2,00 g (10.40 mmol) 
4-fluoro-2-chlorobenzoylchloride 11 in pyridine (13 mL) was refluxed for 1.5 h. The cooled 
mixture was poured into water (100 mL) and the resulting product was filtered off and 
recrystallized from ethanol to obtain a brown powder (1.36 g, 49%); m.p. >300 °C. 
1
H NMR 
(300 MHz, DMSO-d6): /ppm=13.10 (bs, 2H, NH), 7.59–7.51 (m, 4H, Harom.), 7.36–7,30 (m, 
3H, Harom.);
 13
C NMR (75 MHz, DMSO-d6): /ppm= 184.75 (s), 162.40 (s, JCF=247.17 Hz), 
150.84 (s), 137.56 (s, JCF=3.50 Hz), 131.24 (s, JCF=10.75 Hz), 130.86 (s), 130.65 (d, JCF=9.17 
Hz), 124.14 (d, 2C), 120.30 (s), 117.46 (d, JCF=25.01 Hz), 114.83 (d, JCF=21.13 Hz), 112.74 
(d, 2C), 67.77 (s).  
 4.4.2. 2-fluoro-5-ketobenzimidazo1,2-aquinoline-6-carbonitrile 15. 
A solution of 1.00 g (3.37 mmol) 2-(2-benzimidazolyl)-3-keto-(4-fluoro-2-
chlorophenyl)acrylonitrile 13 and 0.88 g t-KOBu in DMF (12 mL) was refluxed for 2 h. After 
cooling, the reaction mixture was evaporated under vacuum and dissolved in water (50 mL). 
Resulting product was filtered off and recrystallized from ethanol to obtain a white powder 
(0.85 g, 96%); m.p. >300 °C. 
1
H NMR (300 MHz, DMSO-d6): /ppm= 8.29 (dd, 1H, J1=6.99 
Hz, J2=8.79 Hz, Harom.), 8.19 (d, 1H, J=8.10 Hz, Harom.), 8.13 (dd, 1H, J1=2.30 Hz, J2=11.06 
Hz, Harom.), 7.48 (dd, 1H, J1=0.84 Hz, J2=7.86 Hz, Harom.), 7.27 (dd, 1H, J1=0.95 Hz, J2=6.20 
Hz, Harom.), 7.23 (dt, 1H, J1=2.19 Hz, J2=8.53 Hz, Harom.), 7.11(dt, 1H, J1=1.10 Hz, J2=7.87 
Hz, Harom.); 
13
C NMR (150 MHz, DMSO-d6): /ppm= 171.64 (s), 163.59 (s, JCF=245.44 Hz), 
154.08 (s), 137.13 (s, JCF=5.85 Hz), 130.90 (s), 128.02 (d, JCF=10.45 Hz), 122.99 (d), 121.30 
(s), 120.27 (s), 119.06 (d), 116.35 (d), 112.31 (d), 110.33 (d, JCF=21.68 Hz), 101.83 (d, 
JCF=27.06 Hz), 73.59 (s). 
4.4.3. 5-chloro-2-fluorobenzimidazo1,2-aquinoline-6-carbonitrile 17. 
A solution of 0.60 g (2.15 mmol) 2-fluoro-5-ketobenzimidazo1,2-aquinoline-6-carbonitrile 
and 0.24 g (1.15 mmol) PCl5 in POCl3 (12 mL) was refluxed for 1.5 h. After cooling, the 
reaction mixture was evaporated under vacuum and dissolved in water (10 ml). Resulting 
product was filtered off and washed with water to obtain a yellow powder (0.62 g, 96%); m.p. 
250–257 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.71 (d, 1H, J=8.49 Hz, Harom.), 8.58 
(dd, 1H, J1=2.27 Hz, J2=10.37 Hz, Harom.), 8.41 (dd, 1H, J1=6.06 Hz, J2=9.12 Hz, Harom.), 8.00 
(dd, 1H, J1=1.32 Hz, J2=7.67 Hz, Harom.), 7.67–7.60 (m, 2H, Harom.), 7.57 (dt, 1H, J1=1.34 Hz, 
J2=7.61 Hz, Harom.); 
13
C NMR (150 MHz, DMSO-d6): /ppm= 165.29 (s, JCF=253.77 Hz), 
144.34 (s), 143.82 (s), 142.18 (s), 136.82 (s, JCF=12.18 Hz), 130.91 (d, JCF=10.95 Hz), 130.21 
(s), 125.66 (d), 124.13 (d), 120.27 (d), 116.32 (s, JCF=1.61 Hz), 114.99 (d), 114.01 (d, 
JCF=23.40 Hz), 113.32 (s), 103.43 (d, JCF=27.53 Hz), 101.64 (s). 
4.4.4. General method for preparation of compounds 23–39 
Compounds 23–39 were prepared using microwave irradiation, at optimized reaction 
time with power 800 W and 40 bar pressure, from compound 17 in acetonitrile (10 mL) with 
excess of added corresponding amine. After cooling, the reaction mixture was filtered off and 
resulting product was separated by column chromatography on SiO2 using 
dichloromethane/methanol as eluent.  
4.4.4.1. 2,5-di-(N-methylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 23. 
Compound 23 was prepared using above described method from 17 (50 mg, 0.50 mmol) and a 
33% solution of methylamine in ethanol (0.26 mL, 1.90 mmol) after 12 h of irradiation to 
yield 35 mg (57%) of light brown powder; m.p. >280 °C. 
1
H NMR (300 MHz, DMSO-d6): 
/ppm= 8.29 (d, 1H, J=8.07 Hz, Harom.), 8.08 (d, 1H, J=9.21 Hz, Harom.), 7.89 (d, 1H, J=5.16 
Hz, NH), 7.69 (dd, 1H, J1=0.78 Hz, J2=7.89 Hz, Harom.), 7.55 (d, 1H, J=1.62 Hz, Harom.), 7.41 
(t, 1H, J=7.52 Hz, Harom.), 7.33 (dt, 1H, J1=1.03 Hz, J2=7.73 Hz, Harom.), 7.06 (d, 1H, J=4.62 
Hz, NH), 6.78 (dd, 1H, J1=1.86 Hz, J2=9.18 Hz, Harom.), 3.39 (d, 3H, J=4.98 Hz, CH3), 2.93 
(d, 3H, J=4.59 Hz, CH3); 
13
C NMR (75 MHz, DMSO-d6): /ppm= 153.99 (s, 2C), 152.41 (s), 
137.26 (s), 131.06 (s), 126.07 (d), 124.61 (d), 121.41 (d), 118.93 (s), 117.96 (d), 113.94 (d), 
109.72 (d), 104.98 (s), 96.56 (d), 94.79 (s), 82.64 (s), 32.41 (q), 29.74 (q); Found: C, 71.60; 
H, 5.09; N, 23.31. Calc. for C18H15N5: C, 71.74; H, 5.02; N, 23.24%; MS (ESI): m/z= 302.4 
([M+1]
+
). 
4.4.4.2. 2,5-di-(N-butylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 24. 
Compound 24 was prepared using above described method from 17 (100 mg, 0.34 mmol) and 
n-butylamine (0.18 mL, 1.80 mmol) after 4 h of irradiation to yield 75 mg (57%) of light 
yellow powder; m.p. 150–153 °C. 1H NMR (600 MHz, DMSO-d6): /ppm= 8.26 (d, 1H, 
J=8.22 Hz, Harom.), 8.16 (d, 1H, J=9.18 Hz, Harom.), 7.67 (d, 1H, J=7.86 Hz, Harom.), 7.64 (t, 
1H, J=6.09 Hz, NH), 7.61 (s, 1H, Harom.), 7.37 (t, 1H, J=7.67 Hz, Harom.), 7.28 (dt, 1H, J1=1.08 
Hz, J2=7.76 Hz, Harom.), 6.94 (t, 1H, J=5.22 Hz, NH), 6.77 (dd, 1H, J1=1.98 Hz, J2=9.18 Hz, 
Harom.), 3.81 (q, 2H, J=6.88 Hz, CH2), 3.25 (q, 2H, J=6.36 Hz, CH2), 1.74 (m, 1H, CH2), 1.63 
(m, 2H, CH2), 1.46 (m, 2H, CH2), 1.42 (m, 2H, CH2), 0.96 (t, 3H, J=7.38 Hz, CH3), 0.94 (t, 
3H, J=7.38 Hz, CH3); 
13
C NMR (75 MHz, DMSO-d6): /ppm= 153.19 (s), 151.18 (s), 150.61 
(s), 145.43 (s), 137.37 (s), 131.28 (s), 126.40 (d), 124.08 (d), 120.98 (d), 119.06 (s), 118.42 
(d), 113.74 (d), 109.01 (d), 105.08 (s), 97.17 (d), 68.35 (s), 44.09 (t), 42.51 (t), 32.27 (t), 
31.09 (t), 20.25 (t), 19.72 (t), 14.24 (q, 2C); Found: C, 74.75; H, 7.00; N, 18.25. Calc. for 
C24H27N5: C, 74.72; H, 7.06; N, 18.17%; MS (ESI): m/z= 386.5 ([M+1]
+
). 
4.4.4.3. 2,5-di-(N-i-propylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 25. 
Compound 25 was prepared using above described method from 17 (100 mg, 0.34 mmol) and 
i-propylamine (0.40 mL, 2.35 mmol) after 7 h of irradiation to yield 31 mg (26%) of white 
powder; m.p. 240–245 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.27 (d, 1H, J=8.19 Hz, 
Harom.), 8.21 (d, 1H, J=9.24 Hz, Harom.), 7.68 (d, 1H, J=7.80 Hz, Harom.), 7.62 (d, 1H, J=1.30 
Hz, Harom.), 7.38 (t, 1H, J=7.56 Hz, Harom.), 7.29 (t, 1H, J=7.40 Hz, Harom.), 7.11 (d, 1H, J=8.55 
Hz, NH), 6.90 (d, 1H, J=7.68 Hz, NH), 6.78 (dd, 1H, J1=1.29 Hz, J2=9.03 Hz, Harom.), 4.83–
4.72 (m, 1H, CH), 3.91–3.80 (m, 1H, CH), 1.38 (t, 6H, J=6.30 Hz, CH3), 1.25 (t, 6H, J=6.27 
Hz, CH3); 
13
C NMR (75 MHz, DMSO-d6): /ppm= 152.37 (s, 2C), 152.33 (s), 150.53 (s), 
145.44 (s), 137.49 (s), 131.28 (s), 126.93 (d), 124.10 (d), 121.02 (d), 118.93 (s), 118.45 (d), 
113.73 (d), 109.14 (d), 105.06 (s), 97.56 (d), 68.90 (s), 46.12 (d), 43.66 (d), 23.67 (q, 2C), 
22.78 (q, 2C); Found: C, 73.84; H, 6.53; N, 19.63. Calc. for C22H23N5: C, 73.92; H, 6.49; N, 
19.59%; MS (ESI): m/z= 358.2 ([M+1]
+
). 
4.4.4.4. 2,5-di-(N-i-butylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 26. 
Compound 26 was prepared using above described method from 17 (100 mg, 0.34 mmol) and 
i-butylamine (0.50 mL, 5.04 mmol) after 6 h of irradiation to yield 25 mg (19%) of yellow 
crystals; m.p. 128–133 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.29 (d, 1H, J=8.10 Hz, 
Harom.), 8.19 (d, 1H, J=9.24 Hz, Harom.), 7.76 (t, 1H, J=6.16 Hz, NH), 7.68 (d, 1H, J=7.86 Hz, 
Harom.), 7.67 (s, 1H, Harom.), 7.37 (t, 1H, J=7.37 Hz, Harom.), 7.30 (dt, 1H, J1=1.05 Hz, J2=7.67 
Hz, Harom.), 7.04 (t, 1H, J=5.48 Hz, NH), 6.81 (dd, 1H, J1=1.64 Hz, J2=9.17 Hz, Harom.), 3.62 
(t, 2H, J=6.63 Hz, CH2), 3.10 (t, 2H, J=6.11 Hz, CH2), 2.20–2.11 (m, 1H, CH), 1.99–1.91 (m, 
1H, CH), 1.03 (d, 6H, J=6.66 Hz, CH3), 0.98 (d, 6H, J=6.63 Hz, CH3); 
13
C NMR (75 MHz, 
DMSO-d6): /ppm= 153.39 (s), 151.25 (s), 150.60 (s), 145.44 (s), 137.39 (s), 131.29 (s), 
126.41 (d), 124.08 (d), 120.97 (d), 118.97 (s), 118.43 (d, 2C), 113.73 (d, 2C), 105.11 (s), 
51.38 (t), 50.60 (t), 28.72 (d), 28.13 (d), 20.83 (q, 2C), 20.04 (q, 2C); Found: C, 74.25; H, 
7.10; N, 18.56. Calc. for C24H27N5: C, 74.77; H, 7.06; N, 18.17%; MS (ESI): m/z= 386.3 
([M+1]
+
). 
4.4.4.5. 2,5-di-(N-i-pentylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 27. 
Compound 27 was prepared using above described method from 17 (200 mg, 0.72 mmol) and 
i-pentylamine (0.17 mL, 1.50 mmol) after 6 h of irradiation to yield 34 mg (28%) of white 
powder; m.p. 111–113 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.27 (d, 1H, J=8.19 Hz, 
Harom.), 8.13 (d, 1H, J=9.26 Hz, Harom.), 7.68 (d, 1H, J=7.48 Hz, Harom.), 7.62 (s, 1H, Harom.), 
7.61 (t, 1H, J=5.68 Hz, NH), 7.38 (t, 1H, J=7.66 Hz, Harom.), 7.28 (t, 1H, J=7.83 Hz, Harom.), 
6.93 (t, 1H, J=4.63 Hz, NH), 6.78 (d, 1H, J=9.26 Hz, Harom.), 3.85 (q, 2H, J=6.88 Hz, CH2 ), 
3.26 (q, 2H, J=7.48 Hz, CH2), 1.81–1.69 (m, 2H, CH), 1.66 (q, 2H, J=7.12 Hz, CH2), 1.55 (q, 
2H, J=6.77 Hz, CH2), 0.97 (d, 6H, J=5.26 Hz, CH3), 0.94 (d, 6H, J=5.33 Hz, CH3); 
13
C NMR 
(150 MHz, DMSO-d6): /ppm= 157.72 (s), 150.90 (s), 150.13 (s), 145.06 (s), 136.99 (s), 
130.86 (s), 130.52 (s), 125.91 (d), 123.55 (d), 120.92 (d), 118.34 (s), 117.97(d), 113.18 (d), 
108.11 (d), 104.86 (s), 96.85 (d), 40.65 (t), 40.16 (t), 38.47 (t), 37.51 (t), 25.39 (d), 25.28 (d), 
22.40 (q, 4C); Found: C, 75.37; H, 7.54; N, 17.09. Calc. for C26H31N5: C, 75.51; H, 7.56; N, 
16.93%; MS (ESI): m/z= 414.3 ([M+1]
+
). 
4.4.4.6. 2,5-di-(N-hexylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 28. 
Compound 28 was prepared using above described method from 17 (100 mg, 0.36 mmol) and 
hexylamine (0.27 mL, 3.90 mmol) after 6 h of irradiation to yield 58 mg (41%) of light 
yellow powder; m.p. 156–160 °C. 1H NMR (600 MHz, DMSO-d6): /ppm= 8.26 (d, 1H, 
J=8.13 Hz, Harom.), 8.13 (d, 1H, J=9.15 Hz, Harom.), 7.69 (s, 1H, Harom.), 7.68 (d, 1H, J=7.42 
Hz, Harom.), 7.61 (s, 1H, NH), 7.37 (t, 1H, J=7.44 Hz, Harom.), 7.28 (dt, 1H, J1=0.99 Hz, 
J2=7.68 Hz, Harom.), 6.97 (t, 1H, J=5.13 Hz, NH), 6.76 (dd, 2H, J1=1.53 Hz, J2=9.09 Hz, 
Harom.), 3.80 (t, 2H, J=6.45 Hz, CH2), 3.24 (q, 2H, J=6.29 Hz, CH2), 1.74 (p, 2H, J=7.29 Hz, 
CH2), 1.64 (p, 2H, J=7.14 Hz, CH2), 1.49–1.37 (m, 4H, CH2), 1.37–1.28 (m, 8H, CH2), 0.89 
(t, 3H, J=6.75 Hz, CH3), 0.87 (t, 3H, J=6.81 Hz, CH3); 
13
C NMR (75 MHz, DMSO-d6): 
/ppm= 153.17 (s), 151.16 (s), 150.62 (s), 145.45 (s), 137.39 (s), 131.29 (s), 126.39 (d), 
124.06 (d, 2C), 120.24 (d, 2C), 118.96 (s), 118.41 (d), 113.72 (d), 105.10 (s), 44.37 (t), 42.88 
(t), 31.69 (t), 31.44 (t), 30.11 (t), 28.97 (t), 26.79 (t), 26.08 (t), 22.58 (t), 22.49 (t), 14.39 (q), 
14.31 (q); Found: C, 76.19; H, 7.96; N, 15.85. Calc. for C28H35N5: C, 76.15; H, 7.99; N, 
15.86%; MS (ESI): m/z= 442.6 ([M+1]
+
). 
4.4.4.7. 2,5-di-(N,N-dimethylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 29. 
Compound 29 was prepared using above described method from 17 (260 mg, 0.88 mmol) and 
dimethylamine (0.90 mL, 13.60 mmol) after 4 h of irradiation to yield 152 mg (52%) of light 
brown powder; m.p. 235–238 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.25 (d, 1H, 
J=8.52 Hz, Harom.), 7.89 (d, 1H, J=9.30 Hz, Harom.), 7.79 (d, 1H, J=7.65 Hz, Harom.), 7.45 (t, 
1H, J=7.46 Hz, Harom.), 7.40 (t, 1H, J=8.25 Hz, Harom.), 7.37 (s, 1H, Harom.), 6.92 (d, 1H, 
J=8.19 Hz, Harom.), 3.29 (s, 6H, CH3), 3.19 (s, 6H, CH3); 
13
C NMR (150 MHz, DMSO-d6): 
/ppm= 158.74 (s), 152.65 (s), 148.57 (s), 144.76 (s), 138.11 (s), 130.41 (s), 129.49 (d), 
124.04 (d), 121.59 (d), 118.68 (d), 117.18 (s), 113.77 (d), 109.29 (d), 107.69 (s), 95.52 (d), 
81.69 (s), 44.57 (q, 2C), 39.81 (q, 2C); Found: C, 72.89; H, 5.83; N, 21.28. Calc. for 
C20H19N5: C, 72.93; H, 5.81; N, 21.26%; MS (ESI): m/z= 330.4 ([M+1]
+
). 
4.4.4.8. 2,5-di-(N,N-diethylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 30. 
Compound 30 was prepared using above described method from 17 (80 mg, 0.27 mmol) and 
diethylamine (0.12 mL, 1.10 mmol) after 5 h of irradiation to yield 36 mg (34%) of yellow 
crystals; m.p. 211–215 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.27 (d, 1H, J=7.65 Hz, 
Harom.), 7.95 (d, 1H, J=9.39 Hz, Harom.), 7.86 (dd, 1H, J1=1.32 Hz, J2=7.56 Hz, Harom.), 7.50 (s, 
1H, Harom.), 7.48 (t, 1H, J=7.60 Hz, Harom.), 7.44 (dt, 1H, J1=1.29 Hz, J2=7.70 Hz, Harom.), 7.01 
(dd, 1H, J1=2.18 Hz, J2=9.41 Hz, Harom.), 3.64 (q, 4H, J=7.03 Hz, CH2), 3.60 (q, 4H, J=7.02 
Hz, CH2), 1.27 (t, 6H, J=7.00 Hz, CH3), 1.16 (t, 6H, J=7.05 Hz, CH3); 
13
C NMR (75 MHz, 
DMSO-d6): /ppm= 158.28 (s), 151.20 (s), 148.51 (s), 145.18 (s), 139.16 (s), 130.93 (s), 
129.83 (d), 124.78 (d), 122.50 (d), 119.56 (d), 117.16 (s), 114.04 (d), 110.24 (d), 109.93 (s), 
95.58 (d), 87.94 (s), 47.53 (t, 2C), 44.93 (t, 2C), 13.56 (q, 2C), 12.66 (q, 2C); Found.: C, 
74.29; H, 7.16; N, 18.55. Calc. for C24H27N5: C, 74.77; H, 7.06; N, 18.17%; MS (ESI): m/z= 
386.5 ([M+1]
+
). 
 
4.4.4.9. 2,5-di-(N,N-dipropylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 31. 
Compound 31 was prepared using above described method from 17 (100 mg, 0.34 mmol) and 
dipropylamine (0.50 mL, 5.90 mmol) after 4 h of irradiation to yield 35 mg (23%) of yellow 
powder; m.p. 223–226 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.23 (d, 1H, J=7.92 Hz, 
Harom.), 7.95 (d, 1H, J=9.39 Hz, Harom.), 7.85 (dd, 1H, J1=1.07 Hz, J2=8.11 Hz, Harom.), 7.50 (t, 
1H, J=7.23 Hz, Harom.), 7.50 (s, 1H), 7.44 (dt, 1H, J1=1.04 Hz, J2=7.31 Hz, Harom.), 7.02 (dd, 
1H, J1=1.88 Hz, J2=9.35 Hz, Harom.), 3.62–3.52 (m, 8H, CH2), 1.78–1.59 (m, 8H, CH2), 1.01 
(t, 6H, J=7.34 Hz, CH3), 0.88 (t, 6H, J=7.31 Hz, CH3); 
13
C NMR (75 MHz, DMSO-d6): 
/ppm= 159.10 (s), 151.52 (s), 148.71 (s), 145.27 (s), 139.14 (s), 130.91 (s), 129.94 (d), 
124.77 (d), 122.24 (d), 119.55 (d), 117.41 (s), 113.85 (d), 110.27 (d), 109.23 (s), 95.85 (d), 
86.46 (s), 55.21 (t, 2C), 52.73 (t, 2C), 21.22 (t, 2C), 20.33 (t, 2C), 11.75 (q, 2C), 11.68 (q, 
2C); Found: C, 76.14; H, 8.06; N, 15.80. Calc. for C28H35N5: C, 76.15; H, 7.99; N, 15.86%; 
MS (ESI): m/z= 442.6 ([M+1]
+
). 
4.4.4.10. 2,5-di-(N,N-dipentylamino)benzimidazo[1,2-a]quinoline-6-carbonitrile 32. 
Compound 32 was prepared using above described method from 17 (150 mg, 0.50 mmol) and 
dipentylamine (0.80 mL, 3.90 mmol) after 4 h of irradiation to yield 75 mg (27%) of yellow 
powder; m.p. 126–128 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.23 (d, 1H, J=8.40 Hz, 
Harom.), 7.92 (d, 1H, J=9.36 Hz, Harom.), 7.84 (d, 1H, J=7.83 Hz, Harom.), 7.50 (t, 1H, J=7.20 
Hz, Harom.), 7.48 (s, 1H, J=1.95 Hz, Harom.), 7.40 (t, 1H, J=7.23 Hz, Harom.), 6.93 (dd, 1H, 
J1=1.82 Hz, J2=9.36 Hz Hz, Harom.), 3.61–3.52 (m, 8H, CH2), 1.72–1.65 (m, 4H, CH2), 1.64–
1.60 (m, 4H, CH2), 1.44–1.63 (m, 8H, CH2), 1.29–1.21 (m, 8H, CH2), 0.92 (t, 6H, J=6.89 Hz, 
CH3), 0.82 (t, 6H, J=6.89 Hz, CH3); 
13
C NMR (150 MHz, DMSO-d6): /ppm= 158.45 (s), 
150.98 (s), 148.21 (s), 144.79 (s), 138.61 (s), 130.40 (s), 129.37 (d), 124.30 (d), 121.52 (d), 
119.06 (d), 116.80 (s), 113.34 (d), 109.70 (d), 108.83 (s), 95.36 (d), 86.15 (s), 52.95 (t, 2C), 
50.62 (t, 2C), 28.64 (t, 2C), 28.44 (t, 2C), 27.07 (t, 2C), 26.22 (t, 2C), 21.99 (t, 2C), 21.77 (t, 
2C), 13.93 (q, 2C), 13.78 (q, 2C); Found: C, 78.06; H, 9.24; N, 12.70. Calc. for C36H51N5: C, 
78.07; H, 9.28; N, 12.65%; MS (ESI): m/z= 554.8 ([M+1]
+
). 
4.2.4.11. 2,5-di-(N-pyrrolidinyl)benzimidazo[1,2-a]quinoline-6-carbonitrile 33. 
Compound 33 was prepared using above described method from 17 (210 mg, 0.70 mmol) and 
pyrrolidine (0.10 mL, 1.22 mmol) after 5 h of irradiation to yield 58 mg (22%) of yellow 
powder; m.p. 265–270 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.16 (d, 1H, J=8.22 Hz, 
Harom.), 7.97 (d, 1H, J=9.24 Hz, Harom.), 7.71 (d, 1H, J=7.68 Hz, Harom.), 7.39 (t, 1H, J=7.56 
Hz, Harom.), 7.31 (t, 1H, J=7.71 Hz, Harom.), 7.19 (d, 1H, J=1.86 Hz, Harom.), 6.63 (dd, 1H, 
J1=1.98 Hz, J2=9.27 Hz, Harom.), 3.93 (t, 4H, J=6.54 Hz, CH2), 3.44 (t, 4H, J=6.24 Hz, CH2), 
2.05–2.03 (m, 4H, CH2), 1.99–1.96 (m, 4H, CH2); 
13
C NMR (150 MHz, DMSO-d6): /ppm= 
154.67 (s), 150.24 (s), 149.63 (s), 145.06 (s), 137.52 (s), 130.55 (s), 129.81 (d), 123.76 (d), 
120.85 (d), 118.77 (s), 118.07 (d), 113.42 (d), 108.60 (d), 106.61 (s), 95.38 (d), 73.78 (s), 
54.03 (t, 2C), 47.47 (t, 2C), 25.33 (t, 2C), 24.94 (t, 2C); Found: C, 75.36; H, 6.13; N, 18.51. 
Calc. for C24H23N5: C, 75.56; H, 6.08; N, 18.36%; MS (ESI): m/z= 382.5 ([M+1]
+
). 
4.4.4.12. 2,5-di-(N-piperidinyl)benzimidazo[1,2-a]quinoline-6-carbonitrile 34.
 
Compound 34 was prepared using above described method from 17 (420 mg, 1.42 mmol) and 
piperidine (0.15 mL, 1.50 mmol) after 10 h of irradiation to yield 150 mg (43%) of yellow 
powder; m.p. 248–250 C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.33 (d, 1H, J=8.34 Hz, 
Harom.), 7.89 (d, 1H, J=2.34 Hz, Harom.), 7.82 (dd, 1H, J1=7.92 Hz, J2=0.90 Hz, Harom.), 7.70 (d, 
1H, J=2.34 Hz, Harom.), 7.48 (dt, 1H, J1=0.90 Hz, J2=7.80 Hz, Harom.), 7.43 (dt, 1H, J1=1.35 
Hz, J2=7.17 Hz, Harom.), 7.23 (dd, 1H, J1=2.40 Hz, J2=9.42 Hz, Harom.), 3.59 (m, 4H, CH2), 
3.54 (t, 4H, J=5.38 Hz, CH2), 1.80 (m, 4H, CH2), 1.70 (m, 8H, CH2); 
13
C NMR (75 MHz, 
DMSO-d6): /ppm= 158.32 (s), 153.41 (s), 148.29 (s), 144.62 (s), 138.33 (s), 130.34 (s), 
128.70 (d), 124.21 (d), 121.95 (d), 118.89 (d), 116.91 (s), 113.93 (d), 111.72 (d), 109.15 (s), 
97.65 (d), 83.63 (s), 53.56 (t, 2C), 47.92 (t, 2C), 26.13 (t, 2C), 24.90 (t, 2C), 23.80 (t), 23.68 
(t); Found: C, 76.05; H, 6.75; N, 17.20. Calc. for C26H27N5: C, 76.25; H, 6.65; N, 17.10%; MS 
(ESI): m/z= 410.5 ([M+1]
+
). 
4.4.4.13. 2,5-di-(N-morpholinyl)benzimidazo[1,2-a]quinoline-6-carbonitrile 35. 
Compound 35 was prepared using above described method from 17 (70 mg, 0.24 mmol) and 
morpholine (0.20 mL, 2.31 mmol) after 5 h of irradiation to yield 73 mg (74%) of yellow 
powder; m.p. >300C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.39 (d, 1H, J=8.16 Hz, 
Harom.), 7.98 (d, 1H, J=9.24 Hz, Harom.), 7.85 (dd, 1H, J1=0.84 Hz, J2=7.89 Hz, Harom.), 7.73 (d, 
1H, J=1.71 Hz, Harom.), 7.50 (t, 1H, J=7.23 Hz, Harom.), 7.43 (dt, 1H, J1=0.93 Hz, J2=7.70 Hz, 
Harom.), 7.23 (dd, 1H, J1=1.83 Hz, J2=9.34 Hz, Harom.), 3.89 (t, 4H, J=4.38 Hz, CH2), 3.84 (t, 
4H, J=5.19 Hz, CH2), 3.59 (t, 4H, J=4.35 Hz, CH2), 3.53 (t, 4H, J=4.69 Hz, CH2); 
13
C NMR 
(150 MHz, DMSO-d6): /ppm= 157.19 (s), 153.81 (s), 147.92 (s), 144.55 (s), 138.19 (s), 
130.33 (s), 128.85 (d), 124.41 (d), 122.18 (d), 119.06 (d), 116.57 (s), 114.26 (d), 111.49 (d), 
109.88 (s), 98.03 (d), 84.90 (s), 66.54 (t, 2C), 65.85 (t, 2C), 52.50 (t, 2C), 46.74 (t, 2C); 
Found: C, 69.62; H, 5.65; N, 16.97. Calc. for C24H23N5O2: C, 69.72; H, 5.61; N, 16.94%; MS 
(ESI): m/z= 414.5 ([M+1]
+
). 
4.4.4.14. 2,5-di-(N-piperazinyl)benzimidazo[1,2-a]quinoline-6-carbonitrile 36. 
Compound 36 was prepared using the above method from 17 (50 mg, 0.17 mmol) and 
piperazine (0.100 g, 1.20 mmol) after 1 h of irradiation to yield 50 mg (72%) of yellow 
crystals; m.p. >300 °C. 
1
H NMR (300 MHz, DMSO-d6): /ppm= 8.39 (d, 1H, J=8.01 Hz, 
Harom.), 7.97 (d, 1H, J=9.33 Hz, Harom.), 7.85 (dd, 1H, J1=1.20 Hz, J2=7.86 Hz, Harom.), 7.73 (d, 
1H, J=1.92 Hz, Harom.), 7.50 (dt, 1H, J1=0.97 Hz, J2=7.57 Hz, Harom.), 7.44 (dt, 1H, J1=1.45 
Hz, J2=7.71 Hz, Harom.), 7.25 (dd, 1H, J1=2.03 Hz, J2=9.40 Hz, Harom.), 3.50 (m, 8H, CH2), 
2.99 (t, 4H, J=4.68 Hz, CH2), 2.93 (t, 4H, J=4.89 Hz, CH2); 
13
C NMR (75 MHz, DMSO-d6): 
/ppm= 158.36 (s), 154.39 (s), 145.06 (s), 138.75 (s), 130.83 (s), 129.30 (d), 124.80 (d), 
122.57 (d), 119.44 (d), 117.33 (s), 114.44 (d), 114.64 (d), 112.04 (d), 109.91 (s), 100.53 (s), 
98.24 (d), 84.42 (s), 54.09 (t, 2C), 48.13 (t, 2C), 46.47 (t, 2C), 45.82 (t, 2C); Found: C, 70.12; 
H, 6.00; N, 23.88. Calc. for C24H25N7: C, 70.05; H, 6.12; N, 23.83%; MS (ESI): m/z= 412.2 
([M+1]
+
). 
4.4.4.15. 2,5-di-[N-(4-N-methylpiperazinyl)]benzimidazo[1,2-a]quinoline-6-carbonitrile 38. 
Compound 38 was prepared using above described method from 17 (100 mg, 0.36 mmol) and 
4-N-methylpiperazine (0.10 mL, 0.90 mmol) after 3 h of irradiation to yield 50 mg (34%) of 
yellow powder; m.p. 250–256 °C. 1H NMR (600 MHz, DMSO-d6): /ppm= 8.38 (d, 1H, 
J=8.28 Hz, Harom.), 7.94 (d, 1H, J=9.36 Hz, Harom.), 7.83 (dd, 1H, J1=0.96 Hz, J2=8.22 Hz, 
Harom.), 7.73 (d, 1H, J=2.16 Hz, Harom.), 7.49 (dt, 1H, J1=0.62 Hz, J2=7.50 Hz, Harom.), 7.43 (d 
t, 1H, J1=1.00 Hz, J2=7.73 Hz, Harom.), 7.25 (dd, 1H, J1=2.22 Hz, J2=9.36 Hz, Harom.), 3.58 (t, 
4H, J=4.80 Hz, CH2), 3.56 (t, 4H, J=5.10 Hz, CH2), 2.62 (bs, 4H, CH2), 2.54 (t, 4H, J=4.92 
Hz, CH2), 2.31 (s, 3H, CH3), 2.27 (s, 3H, CH3); 
13
C NMR (75 MHz, DMSO-d6): /ppm= 
157.46 (s), 153.55 (s), 148.06 (s), 144.55 (s), 138.22 (s), 130.33 (s), 128.74 (d), 124.34 (d), 
122.13 (d), 118.98 (d), 116.69 (s), 114.19 (d), 111.74 (d), 109.56 (s), 98.02 (d), 54.99 (t, 2C), 
54.25 (t, 2C), 52.02 (t, 2C), 45.55 (t, 2C), 45.78 (q), 45.66 (q); Found: C, 71.10; H, 6.73; N, 
22.17. Calc. for C26H29N7: C, 71.04; H, 6.65; N, 22.31%; MS (ESI): m/z= 440.2 ([M+1]
+
). 
4.4.4.16. 2,5-di-[N-(3,5-dimethylpiperazinyl)]benzimidazo[1,2-a]quinoline-6-carbonitrile 39. 
Compound 39 was prepared using above described method from 17 (100 mg, 0.36 mmol) and 
2,6-dimethylpiperazine (0.100 g, 0.90 mmol) after 3 h of irradiation to yield 51 mg (32%) of 
yellow powder; m.p. 233–236 °C. 1H NMR (300 MHz, DMSO-d6): /ppm= 8.27 (d, 1H, 
J=7.95 Hz, Harom.), 7.86 (d, 1H, J=9.36 Hz, Harom.), 7.81 (d, 1H, J=7.56 Hz, Harom.), 7.61 (s, 
1H, Harom.), 7.47 (t, 1H, J=7.68 Hz, Harom.), 7.41 (t, 1H, J=7.29 Hz, Harom.), 7.23 (dd, 1H, 
J1=1.36 Hz, J2=9.68 Hz, Harom.), 3.95 (d, 2H, J=10.74 Hz, CH2), 3.54 (d, 2H, J=11.01 Hz, 
CH2), 3.07 (m, 2H, CH), 3.00 (d, 2H, J=11.25 Hz, CH2), 2.89 (m, 2H, CH), 2.46 (d, 2H, 
J=9.54 Hz, CH2), 1.11 (d, 6H, J=6.18 Hz CH3), 1.05 (d, 6H, J=6.18 Hz CH3); 
13
C NMR (75 
MHz, DMSO-d6): /ppm= 157.71 (s), 153.68 (s), 148.73 (s), 145.09 (s), 138.77 (s), 130.60 
(s), 129.31 (d), 124.71 (d), 122.45 (d), 119.38 (d), 117.29 (s), 114.44 (d), 112.07 (d), 109.65 
(s), 101.52 (s), 98.15(d), 59.34 (t, 2C), 53.65 (t, 2C), 51.43 (d, 2C), 50.56 (d, 2C), 19.65 (q, 
2C), 19.24 (q, 2C); Found: C, 71.72; H, 7.15; N, 21.13. Calc. for C28H33N7: C, 71.92; H, 7.11; 
N, 20.97%; MS (ESI): m/z= 468.2 ([M+1]
+
). 
4.4.5. 2,5-di-[N-(4-N,N-dimethylpiperazin-1-yl])benzimidazo[1,2-a]quinoline-6-carbonitrile 
diiodide 37. 
A mixture of compound 36 (50 mg, 0.12 mmol) and anhydrous potassium carbonate (0.017 g, 
0.11 mmol) was refluxed in acetonitrile (30 mL) with methyl jodide (0.063 mL, 0.96 mmol) 
for 2 h. The reaction mixture was concentrated under reduced pressure to a volume of 5 mL 
and filtered off to yield pure compound 37 as yellow powder (42 mg, 47%); m.p. >300 C.  
1
H NMR (300 MHz, DMSO-d6): /ppm= 8.55 (d, 1H, J=7.95 Hz, Harom.), 8.10 (d, 1H, J=9.30 
Hz, Harom.), 7.91 (dd, 1H, J1=0.93 Hz, J2=7.92 Hz, Harom.), 7.88 (d, 1H, J=1.62 Hz, Harom.), 
7.57 (t, 1H, J=7.27 HZ, Harom.), 7.50 (dt, 1H, J1=1.05 Hz, J2=7.89 Hz, Harom.), 7.32 (dd, 1H, 
J1=1.56 Hz, J2=9.33 Hz, Harom.), 3.97 (t, 8H, J=4.41 Hz, CH2), 3.78 (t, 4H, J=4.34 Hz, CH2), 
3.69 (t, 4H, J=4.74 Hz, CH2), 3.34 (s, 6H, CH3), 3.30 (s, 6H, CH3);
 13
C NMR (150 MHz, 
DMSO-d6): /ppm= 155.95 (s), 152.79 (s), 148.37 (s), 144.50 (s), 138.08 (s), 130.24 (s), 
129.18 (d), 124.75 (d), 122.53 (d), 119.35 (d), 116.21 (s), 114.52 (d), 112.20 (d), 110.37 (s), 
99.09 (d), 86.82 (s), 60.72 (t, 2C), 59.96 (t, 2C), 50.45 (q, 4C), 45.62 (q), 45.66 (t, 2C), 40.95 
(t, 2C); Found: C, 46.39; H, 4.78; N, 13.70. Calc. for C28H35I2N7: C, 46.49; H, 4.88; N, 
13.55%; MS (ESI): m/z= 234.8 ([M+1]
+
). 
 
 
4.3. 3D-QSAR modelling 
 
3D-QSAR models were derived using antiproliferative activity data against against H460, 
HCT 116, MCF-7 of the compounds presented in this paper and similar compounds whose 
antiproliferative activities have been measured in the same laboratory and published 
previously [13, 14]. Altogether 51 compounds were used (Table S1 in the supplement). 
Negative logarithmic values of concentrations that cause 50% growth inhibition of the cell 
lines (pIC50) were used as measure of biological activity for generating 3D- QSAR models. 
For the poorly active compounds whose IC50 values were not explicitly measured, but just 
estimated as “≥10”, ">10", "≥100", "> 100", pIC50 was set to 5.000, 4.301, 4.000, 3.301, 
respectively.   
3D structure of each compound was generated from the SMILES code using VolSurf+ 
3D structure generator. Molecular descriptors for each compound, based on its 3D structure, 
were generated by the VolSurf+ program [15]. Series of 128 descriptors that refer to 
molecular size and shape, to hydrophilic and hydrophobic regions and to the balance between 
them, to the "charge state" descriptors, to lipophilicity, to molecular diffusion, logP, logD, to 
the presence/distribution of pharmacophoric descriptors, to molecular flexibility, to H-bond 
interaction, and to descriptors on some other relevant ADME properties. The definition of all 
128 VolSurf+ descriptors is given in the VolSurf+ manual [15].  
Using Partial Least Square (PLS) analysis, the relationship between the 3D structure-
based molecular descriptors and biological activities was studied. Autoscaling pretreatment, 
by which every variable is the mean centered and scaled to give unit variance, was applied. 
For each cell line, different 3D-QSAR models were generated (models labeled 1, 2, and 3, for 
the cell lines H460, HCT 116, and MCF-7, respectively). The number of significant latent 
variables (nLV) and quality of the models were determined using the leave-one-out (LOO) 
cross-validation procedure. Standard deviation of error of calculation (SDEC) and standard 
deviation of error of prediction (SDEP) were calculated for each model. The PLS coefficients 
of the obtained models were analyzed in order to investigate influence of each descriptor on 
compounds’ antiproliferative activity.  
 
4.4. Antiproliferative evaluation assay 
The experiments were carried out on three human cell lines, which are derived from 
three cancer types: HCT 116 (colon carcinoma), H 460 (lung carcinoma) and MCF-7 (breast 
carcinoma). The cells were cultured as monolayers and maintained in Dulbecco's modified 
Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in a humidified atmosphere with 
5% CO2 at 37 °C. 
 The growth inhibition activity was assessed as described previously [13, 14]. The cell lines 
were inoculated onto a series of standard 96-well microtiter plates on day 0, at 3×10
4
 cells/mL 
(HCT 116, H 460) to 5×10
4
 cells/mL (MCF-7), depending on the doubling times of a specific 
cell line. Test agents were then added in ten-fold dilutions (10
-8
 to 10
-4
 M) and incubated for 
further 72 h. Working dilutions were freshly prepared on the day of testing. After 72 h of 
incubation the cell growth rate was evaluated by performing the MTT assay, which detects 
dehydrogenase activity in viable cells. The absorbance (A) was measured on a microplate 
reader at 570 nm. The absorbance is directly proportional to the number of living, 
metabolically active cells. The percentage of growth (PG) of the cell lines was calculated 
according to one or the other of the following two expressions: 
If (mean Atest – mean Atzero) ≥ 0, then PG = 100 × (mean Atest – mean Atzero) / (mean Actrl – 
meanAtzero). 
If (mean Atest – mean Atzero) < 0, then: PG = 100 × (mean Atest – mean Atzero) / Atzero, where the 
mean Atzero is the average of optical density measurements before exposure of cells to the test 
compound, the mean Atest is the average of optical density measurements after the desired 
period of time and the mean Actrl is the average of optical density measurements after the 
desired period of time with no exposure of cells to the test compound. The results are 
expressed as IC50, which is the concentration necessary for 50% of inhibition. The IC50 values 
for each compound are calculated from concentration-response curves using linear regression 
analysis by fitting the test concentrations that give PG values above and below the reference 
value (i.e. 50%). If however, for all of the tested concentrations produce PGs exceeding the 
respective reference level of effect (e.g. PG value of 50), then the highest tested concentration 
is assigned as the default value, which is preceded by a ">" sign. Minimum two individual 
experiments were carried out and each test point was performed in quadruplicate.  
4.5. DNA binding experiments 
The tested compounds were dissolved in DMSO as 5 or 10 mM stock solutions. CT-DNA 
(Sigma Aldrich, France) was prepared in water and dialyzed overnight. Both were aliquoted 
and stored at -20 °C to then be freshly diluted in the appropriate aqueous buffer. 
4.5.1. DNA melting temperature  
CT-DNA (20 µM) was incubated or not with 10 or 20 µM of the various tested compounds 
(R=drug/base pair ratio of 0.5 or 1) in 1 mL BPE buffer (6 mM Na2HPO4, 2 mM NaH2PO4, 1 
mM EDTA, pH 7.1). The absorbency at 260 nm was measured in quartz cells using an 
Uvikon XL spectrophotometer thermostated with a peltier cryostat every min over a range of 
20 to 100 °C with an increment of 1 °C per min. The Tm values were deduced from the 
midpoint of the hyperchromic transition obtained from first-derivative plots. The variation of 
melting temperature (Tm) were obtained by subtracting the melting temperature 
measurement of CT-DNA alone (control Tm) to that obtained with DNA incubated with the 
compounds (Tm values = Tm[compound + DNA] - Tm[DNA alone]).  
4.5.2. UV/Visible spectroscopy 
The UV/Visible spectra were obtained in a quartz cuvette of 10 mm pathlength containing 
compounds 36 or 37 (20 µM) diluted in 1 mL of BPE buffer in the absence or presence of 
increasing concentrations of CT-DNA (1, 2, 4, 6, 8, 10, 20, 30, 40, 50, 60, 80, 100, 120, 140 
µM). Due to precipitation at higher DNA/drug ratio, spectra were only measured up to 80 µM 
of 9. Each spectrum was recorded from 240 nm to 480 nm using an Uvikon XL 
spectrophotometer and referenced against a cuvette containing DNA at identical 
concentration.  
4.5.3. Fluorescence spectroscopy 
Fluorescence spectra were recorded from 400 to 700 nm essentially as described [16]. The 
fluorescent drugs (10 µM) were diluted in 1 mL of BPE buffer in the presence or absence of 
increasing concentrations of CT-DNA. The quenching constant Ksv was deduced from Stern-
Volmer method where the ratio of fluorescence of the compound alone (F0) over the 
fluorescence of the compound in the presence of CT-DNA (F) is presented as a function of 
CT-DNA concentration. In this configuration, F0/F = 1+Ksv[CT-DNA]. The slope Ksv is 
considered as an equilibrium constant for the static quenching process. 
 4.5.4. Circular dichroism 
For circular dichroism, CT-DNA (50 µM) was incubated with or without (control) increasing 
concentrations of compounds 36 or 37 (1, 5, 10, 20, 30, 40, 50, 60 µM) in BPE. The absence 
of intriniseque CD was validated using the highest concentration of compound (60 µM). The 
CD spectra were collected in a quartz cell of 10 mm path length from 480 to 230 nm using a 
J-810 Jasco spectropolarimeter at a controlled temperature of 20 °C fixed by a PTC-424S/L 
peltier type cell changer (Jasco) as described previously [16]. 
 
4.5.5. Topoisomerase I – mediated DNA relaxation and poisoning activities  
DNA intercalation and topoisomerase I poisoning activities were evaluated using pUC19 
supercoiled plasmid DNA and human topoisomerase I (Topogen, USA) as previously 
described [16, 17]. 
4.5.6. DNase I footprinting 
DNase I footprinting experiments were conducted essentially as described [18]. The gels were 
exposed to storage screen for the appropriated delay at room temperature. The results were 
collected using a Pharos-PMI equipment (BioRad). 
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